Antikörper dringt in Zelle ein
Das kanadische Biotechnologieunternehmen Innexus Biotechnology hat einen Super-Antikörper entwickelt, der in das Innere von Zellen eindringen und dort seine Wirkung entfalten kann. Die neuartigen Antikörper könnten genutzt werden, um Bakterien oder auch Viren innerhalb von Zellen aufzuspüren und zu bekämpfen, berichtet " New Scientist" . Auch gegen veränderte, Krebs erregende Eiweißstoffe würde ein solcher Super-Antikörper wirken. Die Proteinsequenz MTS, die bei bestimmten Signaleiweißstoffen vorkommt, erlaubt das Eindringen.
Super-antibody technology offers hope against cancer
Investors sought after success in early trials
Don Harrison
The Province
Sunday, October 12, 2003
ADVERTISEMENT
InNexus, a small Vancouver/Seattle-based company, is making waves in the biotechnology field with its new super-antibody technology.
Last month, InNexus entered a licensing agreement with the health-biotech arm of the giant U.S. pharmaceutical company Johnson & Johnson.
This week it will join 120 Biotechnology Industry Organization firms at the important BIO VentureForum West investor conference in San Francisco.
BIO represents more than 1,000 biotech companies, academic institutions and government centres researching health care, agricultural, industrial and environmental products in 35 countries.
InNexus`s super-antibody technology, when allied to a specifically programmed antibody, has been shown in early trials on non-Hodgkin`s, B-Cell lymphoma to significantly enhance the killing of cancerous cells.
And because, unlike chemotherapy, super-antibody technology does not also kill surrounding healthy cells, it has company officials hoping for far-reaching applications.
" The super-antibody technology allows you to turn [an existing antibody] into a [more] effective disease fighter," said company CEO Charles Morgan, a former U.S. Cancer Institute official.
dharrison@png.canwest.com
MARCH 11, 2004 - 09:00 ET
InNexus Files for a Significant Expansion to its
Intellectual Property for Antibody-Based Targeting of
Intracellular Molecules
VANCOUVER, BRITISH COLUMBIA--InNexus Biotechnology, Inc. today
announced the filing of additional continuation-in-parts to its
intellectual property, protecting compositions and uses of
SuperAntibody Technology for the targeting of intracellular
molecules.
In December, 2003, InNexus and its collaborators at Immpheron,
Inc., of Lexington, Kentucky and Wright State University School
of Medicine, Dayton, Ohio, announced peer-reviewed publication of
the discovery that monoclonal antibodies can be used to target
intracellular proteins important to the regulation of cellular
activities; specifically the process of genetically regulated
cell-suicide or apoptosis (" MTS-conjugated, anti-active caspase 3
antibodies inhibit actinomycin D-induced apoptosis" , Y Zhao, T L
Brown, H Kohler and S. Muller. Apoptosis 8:631-637, 2003). A
monoclonal antibody to a key enzyme (caspase 3), involved in the
apoptotic cascade, was modified with SuperAntibody technology
which imparted the ability to penetrate into cells without
incurring toxicity. The modified antibody rapidly entered cells,
bound to its target, and inhibited its activity. Thus even with
prior exposure of the cells to the toxic, chemotherapeutic drug,
actinomycin D, the cells did not die. The publication pointed to
an even broader use of InNexus`s cell-penetrating antibodies,
that is, their use as an alternative to some small-molecule, drug
development. Until now, however, antibodies could only be used to
target cell surface molecules. With InNexus`s SuperAntibody
modification, which is simple and non-toxic, important,
intracellular molecules can be targeted with antibodies.
InNexus has now filed additional intellectual property that
further protects its SuperAntibody forms that are able to
penetrate into cells. The patent is the exclusive property of
InNexus and is intended to protect the compositions of matter
(actual drug forms) and the indications (clinical uses) for this
drug development platform.
Dr. Charles Morgan, President of InNexus commented, " We are
especially pleased with the timing of this filing as we are
currently dealing with a great deal of interest in the technology
from Biotechnology and Pharmaceutical companies. The new uses and
drug forms that are protected in this new filing are ones that we
will likely be pursuing with partners in the very near future"
About InNexus
InNexus is developing the next generation of therapeutic,
monoclonal antibodies using its SuperAntibody Technology
Platform. InNexus intends to apply this technology to improve the
potency of existing antibody products, targeted to cell-surface
antigens, while opening new markets and disease applications with
other forms of SuperAntibodies targeting intracellular molecules.
InNexus will develop the technology through partnerships with
biotechnology and pharmaceutical companies while pursuing
development of its own products for unmet medical needs. To learn
more about InNexus please visit the Company`s website:
www.innexusbiotech.com.
Dr. A. Charles Morgan, President
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These statements are not historical facts and are subject to
risks and uncertainties which could cause actual results and the
timing of certain events to differ materially from those set
forth in or implied herein including, without limitation, risks
associated with clinical development, regulatory approvals,
product commercialization, intellectual property claims
litigation and other risks associated with the Company`s proposed
activities.
-30-
FOR FURTHER INFORMATION PLEASE CONTACT:
InNexus Biotechnology, Inc.
Dr. A. Charles Morgan
President
Toll Free: 1-877-990-8382
(425) 696-0068 (FAX)
Email: business@innexusbiotech.com
or
InNexus Biotechnology, Inc.
Investor Relations
Toll Free: 1-888-271-0788
Email: investor@innexusbiotech.com
Website: www.innexusbiotech.com
Directors and Officers:
Dr. A. Charles Morgan, President and Director
Gail Thurston, Director
Thomas Wharton, Director
Stuart Rogers, Chief Financial Officer and Director
Capitalization:
(as of 01-15-2004)
Shares Issued: 16,484,853
Shares in escrow: _4,665,020
Fully diluted: 29,927,041 shares
Held by insiders: 11,000,000 shares
Float (estimated): 11,500,000 shares
Auditor: KPMG LLP, Chartered Accountants
Fiscal Year End: June 30
Transfer Agent: Pacific Corporate Trust Company
Listed: TSX Venture Exchange Symbol: IXS
Cusip #: 45771Q 10 4
Stock Quote and Chart: Stock Quote and Chart
Dieser Artikel ist am 19.4.2004 bei NewScientist.com erschienen
Super-antibodies break the cell barrier
15:23 19 April 04
Exclusive from New Scientist Print Edition. Subscribe and get 4 free issues.
Super-antibodies that can bind to targets within cells, rather than on their surface, could lead to a new range of treatments for diseases, a biotech company claims.
" Most good targets for diseases are inside cells," says Charles Morgan, president of InNexus Biotechnology of Vancouver, Canada, which has developed the super-antibody technology.
Super-antibodies could be used to target bacteria and viruses (including HIV) inside cells, for instance, or abnormal proteins that turn cells cancerous. In theory, they could do everything that the small molecules of most conventional drugs do, and more.
Theraputic antibodies
The beauty of a cell-penetrating super-antibody is that it would be highly discriminating. Because antibodies can be far more specific than small-molecule drugs, and because they are not inherently toxic, they should have fewer side effects.
The big disadvantage is that antibodies have to be injected as they do not survive in the stomach.
Molecular ferries
Antibody-based treatments are already being used to treat diseases in several ways (see graphic). Over a dozen are now approved for use in people. However, like natural antibodies, all bind to molecules on the surface of cells or viruses.
Antibodies under development can ferry other substances into cells, such as the toxin ricin, and they are sometimes engulfed by a cell after binding to its surface proteins, but none can enter cells freely and target molecules inside them.
However, InNexus says a simple chemical modification enables any antibody to flit in and out of cells until it finds its target. The " key" that allows them to enter is a short protein segment called a membrane-translocating sequence (MTS), normally found in signalling proteins such as growth factors that can enter cells. Several groups worldwide have shown that attaching MTS segments to other proteins allows them to enter cells.
" We thought, can you do this with an antibody?" says Morgan, who presented the technology at a BioVentures biotech conference in London earlier in April. InNexus found a way to attach an MTS segment to a structure common to all antibodies. " And lo and behold, it worked," he says.
Experiments with a fluorescently labelled super-antibody show it enters all cells but accumulates only inside cells containing its target, Morgan says. He thinks the antibodies could last in the body for up to a month, entering and leaving cells until they find their target.
Cell suicide
As a proof of principle, the company developed a super-antibody that binds to and blocks caspase-3, an enzyme inside cells that triggers cell suicide. The super-antibody stopped human white blood cells from killing themselves when they were exposed to actinomycin D, a drug that normally triggers cell suicide (Apoptosis, vol 8, p 631).
InNexus hopes a super-antibody of this kind can be developed to block cell death in people who have just had heart attacks or strokes.
Some researchers have their doubts. " A lot of work has been done trying to make antibodies that are stable in cells," says Andrew Bradbury of the Los Alamos National Laboratory in New Mexico. " But it`s proved far more difficult than expected."
But Morgan says an antibody`s stability depends on how it enters the cell. Those that are engulfed after binding to surface proteins end up in structures called endosomes, where they are likely to be destroyed. Super-antibodies, however, enter the normal, safe environment of the cell.
" There would definitely be loads of new targets if it worked," says Daniel Elger of biotech company Antisoma, based in London, UK, which has developed an anti-cancer antibody that carries an enzyme into cells after binding to a surface receptor.
But for purposes like blocking viral replication, the success of cell-penetrating super-antibodies will depend on the concentrations they reach inside cells. " It would be down to the practicality of whether you could get enough in," he says.
Andy Coghlan
www.newscientist.com/news/news.jsp?id=ns99994881
hier die etwas stümperhafte übersetzung mittels eines übersetzungsprogramms
Super-Antikörper, die an Ziele innerhalb der Zellen binden können, anstatt auf ihrer Oberfläche, konnten zu eine neue Strecke der Behandlungen für Krankheiten führen, eine biotechfirma behauptet. " die meisten guten Ziele für Krankheiten sind innere Zellen," , sagt Charles Morgan, Präsident von Biotechnologie InNexus von Vancouver, Kanada, das die Super-Antikörpertechnologie entwickelt hat. Super-Antikörper konnten benutzt werden, um Bakterium und Innerezellen der Viren (einschließlich HIV), zum Beispiel oder anormale Proteine zu zielen, die Zellen cancerous drehen. In der Theorie konnten sie alles tun, das die kleinen Moleküle der meisten herkömmlichen Drogen, und mehr. Antikörper Theraputic die Schönheit eines C\-antikörpers ist, daß er in hohem Grade absondern würde. Weil Antikörper als Kleinmoleküldrogen weites spezifischeres sein können und weil sie nicht in sich selbst giftig sind, sollten sie wenige Nebenwirkungen haben. Der grosse Nachteil ist, daß Antikörper eingespritzt werden müssen, da sie nicht im Magen überleben. Werden molekulare Fähren Antikörper-gegründete Behandlungen bereits verwendet, um Krankheiten in einigen Weisen zu behandeln (sehen Sie Graphik). Über Dutzend werden jetzt für Gebrauch in den Leuten genehmigt. Von jedoch wie natürliche Antikörper, binden alle an Moleküle auf der Oberfläche Zellen oder Viren. Antikörper unter Entwicklungsdosenfähre andere Substanzen in Zellen, wie das Giftstoffricin und sie werden manchmal durch eine Zelle versenkt, nachdem man an seine Oberflächenproteine gebunden hat, aber keine können frei kommen Zellen und Zielmoleküle innerhalb sie. Jedoch sagt InNexus, daß eine einfache chemische Änderung jedem möglichem Antikörper ermöglicht, in und aus Zellen zu huschen, bis sie sein Ziel findet. Der " Schlüssel" , der sie hereinkommen läßt ist ein kurzes Proteinsegment, das eine Membrane-Versetzenreihenfolge (MTS) genannt wird, normalerweise gefunden, wenn es Proteinen wie Wachstumfaktoren signalisiert, die Zellen eintragen können. Einige weltweite Gruppen haben gezeigt, daß die Befestigung von MTS-Segmenten zu anderen Proteinen sie Zellen eintragen läßt. " wir dachten, können Sie dieses mit einem Antikörper tun?" , sagt Morgan, das die Technologie bei einer biotechkonferenz BioVentures in London früh im April darstellte. InNexus fand eine Weise, ein MTS-Segment zu einer Struktur anzubringen, die für alle Antikörper allgemein ist. " und niedrig und behold, funktionierte es," sagt er. Experimente mit einem fluorescently beschrifteten Super-Antikörpererscheinen trägt es ein, alle Zellen aber sammelt nur die inneren Zellen an, die sein Ziel enthalten, sagt Morgan. Er denkt, daß die Antikörper im Körper für bis zu einen Monat dauern konnten und Zellen eintragen und verlassen, bis sie ihr Ziel finden. Zellenselbstmord als Beweis der Grundregel, die Firma entwickelte einen Super-Antikörper, der an bindet und caspase-3 blockiert, ein Enzym innerhalb der Zellen dieser Triggerzellenselbstmord. Der Super-Antikörper stoppte menschliche weiße Blutzellen von der Tötung selbst, als sie Aktinomycin D ausgesetzt wurden, eine Droge, die normalerweise Zellenselbstmord auslöst (Apoptosis, Vol. 8, p 631). InNexus hofft, daß ein Super-Antikörper dieser Art entwickelt werden kann, um Zellentod in den Leuten zu blockieren, die gerade Herzangriffe oder Anschläge gehabt haben. Einige Forscher haben ihre Zweifel. " eine Menge Arbeit ist erfolgtes Versuchen gewesen, Antikörper zu bilden, die in den Zellen beständig sind," sagt Andrew Bradbury des Los Alamos nationalen Labors in neuem Mexiko. " aber es ist nachgewiesenes weit schwierigeres als erwartet." , Aber Morgan sagt, daß die Stabilität eines Antikörpers abhängt davon, wie sie die Zelle einträgt. Die, die versenkt werden, nachdem man surface Proteine gebunden hat, beenden oben in den Strukturen, die endosomes genannt werden, wo sie wahrscheinlich sind zerstört zu werden. Super-Antikörper tragen jedoch das normale, sichere Klima der Zelle ein. " es würde definitiv Lasten der neuen Ziele, wenn es funktionierte," sagt Daniel Elger der biotechfirma Antisoma geben, gegründet in London, Großbritannien, das einen krebsbekämpfenden Antikörper entwickelt hat, der ein Enzym in Zellen trägt, nachdem es zu einem Oberflächenempfänger gebunden hat. Aber zu den Zwecken mögen Sie Virenreproduktion blockieren, der Erfolg der C\-antikörper abhängt von den Konzentrationen, die sie innere Zellen erreichen. " er würde unten zum Praktischen von, ob Sie genug innen erhalten konnten," ihm sagt sein.
finance.yahoo.com/q?d=t&s=IXS.V
hier die jomepage der firma
www.innexusbiotech.com/
insgesamt scheint ein investment aussichtsreich, jedoch bleibt auch ein risiko des totalverlustes möglich. dies ist jedoch bei allen hotstocks möglich und sollte daher mit einkalkuliert werden.
gruss meislo
Das kanadische Biotechnologieunternehmen Innexus Biotechnology hat einen Super-Antikörper entwickelt, der in das Innere von Zellen eindringen und dort seine Wirkung entfalten kann. Die neuartigen Antikörper könnten genutzt werden, um Bakterien oder auch Viren innerhalb von Zellen aufzuspüren und zu bekämpfen, berichtet " New Scientist" . Auch gegen veränderte, Krebs erregende Eiweißstoffe würde ein solcher Super-Antikörper wirken. Die Proteinsequenz MTS, die bei bestimmten Signaleiweißstoffen vorkommt, erlaubt das Eindringen.
Super-antibody technology offers hope against cancer
Investors sought after success in early trials
Don Harrison
The Province
Sunday, October 12, 2003
ADVERTISEMENT
InNexus, a small Vancouver/Seattle-based company, is making waves in the biotechnology field with its new super-antibody technology.
Last month, InNexus entered a licensing agreement with the health-biotech arm of the giant U.S. pharmaceutical company Johnson & Johnson.
This week it will join 120 Biotechnology Industry Organization firms at the important BIO VentureForum West investor conference in San Francisco.
BIO represents more than 1,000 biotech companies, academic institutions and government centres researching health care, agricultural, industrial and environmental products in 35 countries.
InNexus`s super-antibody technology, when allied to a specifically programmed antibody, has been shown in early trials on non-Hodgkin`s, B-Cell lymphoma to significantly enhance the killing of cancerous cells.
And because, unlike chemotherapy, super-antibody technology does not also kill surrounding healthy cells, it has company officials hoping for far-reaching applications.
" The super-antibody technology allows you to turn [an existing antibody] into a [more] effective disease fighter," said company CEO Charles Morgan, a former U.S. Cancer Institute official.
dharrison@png.canwest.com
MARCH 11, 2004 - 09:00 ET
InNexus Files for a Significant Expansion to its
Intellectual Property for Antibody-Based Targeting of
Intracellular Molecules
VANCOUVER, BRITISH COLUMBIA--InNexus Biotechnology, Inc. today
announced the filing of additional continuation-in-parts to its
intellectual property, protecting compositions and uses of
SuperAntibody Technology for the targeting of intracellular
molecules.
In December, 2003, InNexus and its collaborators at Immpheron,
Inc., of Lexington, Kentucky and Wright State University School
of Medicine, Dayton, Ohio, announced peer-reviewed publication of
the discovery that monoclonal antibodies can be used to target
intracellular proteins important to the regulation of cellular
activities; specifically the process of genetically regulated
cell-suicide or apoptosis (" MTS-conjugated, anti-active caspase 3
antibodies inhibit actinomycin D-induced apoptosis" , Y Zhao, T L
Brown, H Kohler and S. Muller. Apoptosis 8:631-637, 2003). A
monoclonal antibody to a key enzyme (caspase 3), involved in the
apoptotic cascade, was modified with SuperAntibody technology
which imparted the ability to penetrate into cells without
incurring toxicity. The modified antibody rapidly entered cells,
bound to its target, and inhibited its activity. Thus even with
prior exposure of the cells to the toxic, chemotherapeutic drug,
actinomycin D, the cells did not die. The publication pointed to
an even broader use of InNexus`s cell-penetrating antibodies,
that is, their use as an alternative to some small-molecule, drug
development. Until now, however, antibodies could only be used to
target cell surface molecules. With InNexus`s SuperAntibody
modification, which is simple and non-toxic, important,
intracellular molecules can be targeted with antibodies.
InNexus has now filed additional intellectual property that
further protects its SuperAntibody forms that are able to
penetrate into cells. The patent is the exclusive property of
InNexus and is intended to protect the compositions of matter
(actual drug forms) and the indications (clinical uses) for this
drug development platform.
Dr. Charles Morgan, President of InNexus commented, " We are
especially pleased with the timing of this filing as we are
currently dealing with a great deal of interest in the technology
from Biotechnology and Pharmaceutical companies. The new uses and
drug forms that are protected in this new filing are ones that we
will likely be pursuing with partners in the very near future"
About InNexus
InNexus is developing the next generation of therapeutic,
monoclonal antibodies using its SuperAntibody Technology
Platform. InNexus intends to apply this technology to improve the
potency of existing antibody products, targeted to cell-surface
antigens, while opening new markets and disease applications with
other forms of SuperAntibodies targeting intracellular molecules.
InNexus will develop the technology through partnerships with
biotechnology and pharmaceutical companies while pursuing
development of its own products for unmet medical needs. To learn
more about InNexus please visit the Company`s website:
www.innexusbiotech.com.
Dr. A. Charles Morgan, President
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These statements are not historical facts and are subject to
risks and uncertainties which could cause actual results and the
timing of certain events to differ materially from those set
forth in or implied herein including, without limitation, risks
associated with clinical development, regulatory approvals,
product commercialization, intellectual property claims
litigation and other risks associated with the Company`s proposed
activities.
-30-
FOR FURTHER INFORMATION PLEASE CONTACT:
InNexus Biotechnology, Inc.
Dr. A. Charles Morgan
President
Toll Free: 1-877-990-8382
(425) 696-0068 (FAX)
Email: business@innexusbiotech.com
or
InNexus Biotechnology, Inc.
Investor Relations
Toll Free: 1-888-271-0788
Email: investor@innexusbiotech.com
Website: www.innexusbiotech.com
Directors and Officers:
Dr. A. Charles Morgan, President and Director
Gail Thurston, Director
Thomas Wharton, Director
Stuart Rogers, Chief Financial Officer and Director
Capitalization:
(as of 01-15-2004)
Shares Issued: 16,484,853
Shares in escrow: _4,665,020
Fully diluted: 29,927,041 shares
Held by insiders: 11,000,000 shares
Float (estimated): 11,500,000 shares
Auditor: KPMG LLP, Chartered Accountants
Fiscal Year End: June 30
Transfer Agent: Pacific Corporate Trust Company
Listed: TSX Venture Exchange Symbol: IXS
Cusip #: 45771Q 10 4
Stock Quote and Chart: Stock Quote and Chart
Dieser Artikel ist am 19.4.2004 bei NewScientist.com erschienen
Super-antibodies break the cell barrier
15:23 19 April 04
Exclusive from New Scientist Print Edition. Subscribe and get 4 free issues.
Super-antibodies that can bind to targets within cells, rather than on their surface, could lead to a new range of treatments for diseases, a biotech company claims.
" Most good targets for diseases are inside cells," says Charles Morgan, president of InNexus Biotechnology of Vancouver, Canada, which has developed the super-antibody technology.
Super-antibodies could be used to target bacteria and viruses (including HIV) inside cells, for instance, or abnormal proteins that turn cells cancerous. In theory, they could do everything that the small molecules of most conventional drugs do, and more.
Theraputic antibodies
The beauty of a cell-penetrating super-antibody is that it would be highly discriminating. Because antibodies can be far more specific than small-molecule drugs, and because they are not inherently toxic, they should have fewer side effects.
The big disadvantage is that antibodies have to be injected as they do not survive in the stomach.
Molecular ferries
Antibody-based treatments are already being used to treat diseases in several ways (see graphic). Over a dozen are now approved for use in people. However, like natural antibodies, all bind to molecules on the surface of cells or viruses.
Antibodies under development can ferry other substances into cells, such as the toxin ricin, and they are sometimes engulfed by a cell after binding to its surface proteins, but none can enter cells freely and target molecules inside them.
However, InNexus says a simple chemical modification enables any antibody to flit in and out of cells until it finds its target. The " key" that allows them to enter is a short protein segment called a membrane-translocating sequence (MTS), normally found in signalling proteins such as growth factors that can enter cells. Several groups worldwide have shown that attaching MTS segments to other proteins allows them to enter cells.
" We thought, can you do this with an antibody?" says Morgan, who presented the technology at a BioVentures biotech conference in London earlier in April. InNexus found a way to attach an MTS segment to a structure common to all antibodies. " And lo and behold, it worked," he says.
Experiments with a fluorescently labelled super-antibody show it enters all cells but accumulates only inside cells containing its target, Morgan says. He thinks the antibodies could last in the body for up to a month, entering and leaving cells until they find their target.
Cell suicide
As a proof of principle, the company developed a super-antibody that binds to and blocks caspase-3, an enzyme inside cells that triggers cell suicide. The super-antibody stopped human white blood cells from killing themselves when they were exposed to actinomycin D, a drug that normally triggers cell suicide (Apoptosis, vol 8, p 631).
InNexus hopes a super-antibody of this kind can be developed to block cell death in people who have just had heart attacks or strokes.
Some researchers have their doubts. " A lot of work has been done trying to make antibodies that are stable in cells," says Andrew Bradbury of the Los Alamos National Laboratory in New Mexico. " But it`s proved far more difficult than expected."
But Morgan says an antibody`s stability depends on how it enters the cell. Those that are engulfed after binding to surface proteins end up in structures called endosomes, where they are likely to be destroyed. Super-antibodies, however, enter the normal, safe environment of the cell.
" There would definitely be loads of new targets if it worked," says Daniel Elger of biotech company Antisoma, based in London, UK, which has developed an anti-cancer antibody that carries an enzyme into cells after binding to a surface receptor.
But for purposes like blocking viral replication, the success of cell-penetrating super-antibodies will depend on the concentrations they reach inside cells. " It would be down to the practicality of whether you could get enough in," he says.
Andy Coghlan
www.newscientist.com/news/news.jsp?id=ns99994881
hier die etwas stümperhafte übersetzung mittels eines übersetzungsprogramms
Super-Antikörper, die an Ziele innerhalb der Zellen binden können, anstatt auf ihrer Oberfläche, konnten zu eine neue Strecke der Behandlungen für Krankheiten führen, eine biotechfirma behauptet. " die meisten guten Ziele für Krankheiten sind innere Zellen," , sagt Charles Morgan, Präsident von Biotechnologie InNexus von Vancouver, Kanada, das die Super-Antikörpertechnologie entwickelt hat. Super-Antikörper konnten benutzt werden, um Bakterium und Innerezellen der Viren (einschließlich HIV), zum Beispiel oder anormale Proteine zu zielen, die Zellen cancerous drehen. In der Theorie konnten sie alles tun, das die kleinen Moleküle der meisten herkömmlichen Drogen, und mehr. Antikörper Theraputic die Schönheit eines C\-antikörpers ist, daß er in hohem Grade absondern würde. Weil Antikörper als Kleinmoleküldrogen weites spezifischeres sein können und weil sie nicht in sich selbst giftig sind, sollten sie wenige Nebenwirkungen haben. Der grosse Nachteil ist, daß Antikörper eingespritzt werden müssen, da sie nicht im Magen überleben. Werden molekulare Fähren Antikörper-gegründete Behandlungen bereits verwendet, um Krankheiten in einigen Weisen zu behandeln (sehen Sie Graphik). Über Dutzend werden jetzt für Gebrauch in den Leuten genehmigt. Von jedoch wie natürliche Antikörper, binden alle an Moleküle auf der Oberfläche Zellen oder Viren. Antikörper unter Entwicklungsdosenfähre andere Substanzen in Zellen, wie das Giftstoffricin und sie werden manchmal durch eine Zelle versenkt, nachdem man an seine Oberflächenproteine gebunden hat, aber keine können frei kommen Zellen und Zielmoleküle innerhalb sie. Jedoch sagt InNexus, daß eine einfache chemische Änderung jedem möglichem Antikörper ermöglicht, in und aus Zellen zu huschen, bis sie sein Ziel findet. Der " Schlüssel" , der sie hereinkommen läßt ist ein kurzes Proteinsegment, das eine Membrane-Versetzenreihenfolge (MTS) genannt wird, normalerweise gefunden, wenn es Proteinen wie Wachstumfaktoren signalisiert, die Zellen eintragen können. Einige weltweite Gruppen haben gezeigt, daß die Befestigung von MTS-Segmenten zu anderen Proteinen sie Zellen eintragen läßt. " wir dachten, können Sie dieses mit einem Antikörper tun?" , sagt Morgan, das die Technologie bei einer biotechkonferenz BioVentures in London früh im April darstellte. InNexus fand eine Weise, ein MTS-Segment zu einer Struktur anzubringen, die für alle Antikörper allgemein ist. " und niedrig und behold, funktionierte es," sagt er. Experimente mit einem fluorescently beschrifteten Super-Antikörpererscheinen trägt es ein, alle Zellen aber sammelt nur die inneren Zellen an, die sein Ziel enthalten, sagt Morgan. Er denkt, daß die Antikörper im Körper für bis zu einen Monat dauern konnten und Zellen eintragen und verlassen, bis sie ihr Ziel finden. Zellenselbstmord als Beweis der Grundregel, die Firma entwickelte einen Super-Antikörper, der an bindet und caspase-3 blockiert, ein Enzym innerhalb der Zellen dieser Triggerzellenselbstmord. Der Super-Antikörper stoppte menschliche weiße Blutzellen von der Tötung selbst, als sie Aktinomycin D ausgesetzt wurden, eine Droge, die normalerweise Zellenselbstmord auslöst (Apoptosis, Vol. 8, p 631). InNexus hofft, daß ein Super-Antikörper dieser Art entwickelt werden kann, um Zellentod in den Leuten zu blockieren, die gerade Herzangriffe oder Anschläge gehabt haben. Einige Forscher haben ihre Zweifel. " eine Menge Arbeit ist erfolgtes Versuchen gewesen, Antikörper zu bilden, die in den Zellen beständig sind," sagt Andrew Bradbury des Los Alamos nationalen Labors in neuem Mexiko. " aber es ist nachgewiesenes weit schwierigeres als erwartet." , Aber Morgan sagt, daß die Stabilität eines Antikörpers abhängt davon, wie sie die Zelle einträgt. Die, die versenkt werden, nachdem man surface Proteine gebunden hat, beenden oben in den Strukturen, die endosomes genannt werden, wo sie wahrscheinlich sind zerstört zu werden. Super-Antikörper tragen jedoch das normale, sichere Klima der Zelle ein. " es würde definitiv Lasten der neuen Ziele, wenn es funktionierte," sagt Daniel Elger der biotechfirma Antisoma geben, gegründet in London, Großbritannien, das einen krebsbekämpfenden Antikörper entwickelt hat, der ein Enzym in Zellen trägt, nachdem es zu einem Oberflächenempfänger gebunden hat. Aber zu den Zwecken mögen Sie Virenreproduktion blockieren, der Erfolg der C\-antikörper abhängt von den Konzentrationen, die sie innere Zellen erreichen. " er würde unten zum Praktischen von, ob Sie genug innen erhalten konnten," ihm sagt sein.
finance.yahoo.com/q?d=t&s=IXS.V
hier die jomepage der firma
www.innexusbiotech.com/
insgesamt scheint ein investment aussichtsreich, jedoch bleibt auch ein risiko des totalverlustes möglich. dies ist jedoch bei allen hotstocks möglich und sollte daher mit einkalkuliert werden.
gruss meislo
